I am very encouraged by the results of the VTI InterFuse lateral system that allows for a large vertebral footprint with less soft tissue distraction.
MINNEAPOLIS (PRWEB) March 26, 2019
Vertebral Technologies, Inc. (VTI) announces the presentation of clinical results on their InterFuse® lateral system at the 2019 International Society for the Advancement of Spine Surgery (ISASS) conference in Anaheim, California. VTI is a spine technology company focused on creating modular implants for painful spine conditions that improve minimally invasive surgery (MIS) outcomes. Renowned orthopedic surgeon Dr. Reginald Knight of Cooperstown, New York, will present the study findings on April 3 at 2:46 p.m. during the ISAAS 2019 Oral Poster Lightning Rounds at the Anaheim Convention Center.
The InterFuse lateral system results, entitled "Approach Related Paresthesia Following Transpsoas Lumbar Interbody Fusion with VTI Implant," follows a clinical study with Dr. Knight’s patients. Dr. Knight is director of the Bassett Spine Care Institute and vice president of medical affairs at A.O. Fox Hospital in Oneonta, New York.
“I am very encouraged by the results of the VTI InterFuse lateral system that allows for a large vertebral footprint with less soft tissue distraction,” said Dr. Knight. “The reduction in postoperative patient reported nerve injury is significant and compares very well to published literature.”
From October 2013 through September 2018, Dr. Knight treated 35 patients with lumbar degenerative conditions using VTI’s InterFuse lateral system. All of the patients, regardless of new paresthesia, reported significant improvement—with no revision surgery required. The new onset paresthesia of 14 percent reported in the study is greater than 50 percent improvement over other published outcomes(1). In addition, zero percent postoperative motor deficits in the study is reported to be as high as 24 percent in literature.
"These clinical results of our first-generation InterFuse lateral system helps validate that nerve injury attributable to transpsoas retraction in lateral surgery can be minimized with the patented modularity the InterFuse lateral system offers,” said Paul Hickey, president and CEO of VTI. “We are excited about these initial results validating our competitive technology that allows for a simplified access channel – one that is almost 50 percent smaller than other available lateral implants.”
For more information about VTI’s InterFuse system, visit http://www.vti-spine.com or contact Paul Hickey at email@example.com, +1.877.912.5401.
To attend Dr. Knights presentation of the VTI clinical study results, register for the 2019 ISASS conference at https://www.isass.org.
About The InterFuse Techology
VTI’s InterFuse lateral system’s patented minimally invasive technology platform has FDA clearance and allows surgeons to deliver a modular interbody device in small segments requiring smaller muscle and tissue dissection and nerve root retraction than typically seen for interbody fusion. The implant which is assembled in the affected disc space results in a large, stable, load-bearing surface that is favorable for interbody fusion surgery. The company’s first FDA cleared device, the InterFuse S™, has been available for sale in the United States since 2008.
About Vertebral Technologies, Inc.
Vertebral Technologies, Inc. (VTI) is a privately held company based in Minneapolis, MN, USA. VTI is dedicated to the commercialization of innovative medical devices to address painful conditions of the spine through differentiated, less-invasive surgical approaches. Founded in 2005, VTI’s products utilize its unique modular-assembly technology to deliver solutions optimized for both surgeons and their patients. VTI has 23 U.S. issued patents and has sold over 7,000 InterFuse modular interbody fusion devices worldwide to-date.
(1)Lykissas, M. G., Aichmair, A., Hughes, A. P., Sama, A. A., Lebl, D. R., Taher, F., ... & Girardi, F. P. (2014). Nerve injury after lateral lumbar interbody fusion: a review of 919 treated levels with identification of risk factors. The Spine Journal, 14(5), 749-758.